New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Ramsey Baghdadi
Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
The 'Dead Cat' Strikes Back: What Does US FDA Do With A Challenging Panel Outcome?
Akcea’s volanesorsen for familial chylomicronemia syndrome barely made it through advisory committee due to a rare but unpredictable and rapidly presenting adverse event that likely can’t be resolved with a REMS. Now what?
FDA Pulmonary/Rheumatology Division Sees Management Shakeup
Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.
It's NTAP Season!
In a Pink Sheet podcast, Prevision Policy analysts discuss the US Medicare program's new technology add-on payment process.
The Sarepta Precedent: The Good, The Bad, And The Ugly
Podcast discussion of three broader precedents stemming from US FDA's original Exondys 51 approval.
Grading Gottlieb: A Podcast Report Card
Prevision policy experts discuss where US FDA commissioner has been most effective, room for improvement, and what would make for a second successful year.
Generics, Budgeting, And The Stubborn Persistence Of Cost Savings
ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.
Advertisement